As of November 15, 2026, Adma Biologics, Inc. is a publicly traded company (Nasdaq: ADMA); its largest reported holder is State Street, with 6.1% on Schedule 13G of November 10, 2026, then Vanguard (5.08%). The largest insider holding is Adam S. Grossman, the chief executive and president, with 2,651,734 shares (1.2% of shares outstanding), per Form 4 of November 5, 2026 (Schedule 13G, November 10, 2026).
Is this your company?
About to sign with, pay or invest in Adma Biologics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Adma Biologics, Inc. a real, registered company?
- Adma Biologics Inc files with the SEC under CIK 1368514 (its SEC filings).
- Its shares are listed under the ticker ADMA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Ramsey, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ADMA BIOLOGICS INC in our court records and SEC 8-K records (as of 2026-11-15).
- Leadership changes: the latest reported is Brad Tade, Chief Financial Officer (Form 8-K filed 2026-02-25). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-11-10).
Who are Adma Biologics, Inc.'s owners and officers?
Adma Biologics, Inc.: incorporated in Delaware; business address in Ramsey, New Jersey; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-10).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-10 | State Street Corporation | 6.1% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 7.4% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.08% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-12 | Invesco LTD. | 5% |
| Schedule 13G, 2025-08-11 | State Street Corporation | 5.1% |
| Schedule 13G/A, 2025-07-29 | The Vanguard Group | 8.94% |
Questions about who owns Adma Biologics, Inc.
Who owns Adma Biologics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Adma Biologics, Inc.: State Street Corporation (6.1%, Schedule 13G, filed 2026-11-10), Vanguard Capital Management (5.08%, Schedule 13G, filed 2026-04-29) and Invesco LTD. (5%, Schedule 13G/A, filed 2026-02-12).
Who are the largest shareholders of Adma Biologics, Inc.?
By the share each holder's latest filing reports, the largest holders of Adma Biologics, Inc. on this page are State Street Corporation (6.1%), Vanguard Capital Management (5.08%) and Invesco LTD. (5%).
When did State Street Corporation buy into Adma Biologics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from State Street Corporation on this page is the Schedule 13G, filed 2025-08-11, reporting 5.1%; its latest, Schedule 13G filed 2026-11-10, reports 6.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Adma Biologics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Adma Biologics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Adma Biologics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-02-25 | Brad Tade | Chief Financial Officer | departed | |
| Form 8-K, 2026-02-25 | Terry Kohler | Chief Financial Officer | appointed | 2026-02-26 |
Which insiders own Adma Biologics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 2,651,734 shares (1.2% of shares outstanding), 2,070,777 held directly and 580,957 indirectly (Form 4, 2026-11-05).
- , a director: 2,143,750 shares (0.97% of shares outstanding), 98,020 held directly and 2,045,730 indirectly (Form 4, 2026-03-09).
- , a director: 520,459 shares (0.23% of shares outstanding), 520,284 held directly and 175 indirectly (Form 4, 2026-05-28).
- , the chief operating officer and senior vice president: 443,061 shares (0.20% of shares outstanding) (Form 4, 2026-07-28).
- , a director: 322,030 shares (0.15% of shares outstanding), 241,040 held directly and 80,990 indirectly (Form 4, 2026-03-17).
Shares outstanding: 221,854,389 as of 2026-10-30, from the company's latest SEC cover page.
How much has Adma Biologics, Inc. raised?
No fundraising or offering filing from Adma Biologics, Inc. is on file with us.
Keep reading
More on Adma Biologics, Inc. and the records around it.
Adma Biologics, Inc. elsewhere on the record
- Leadership changes Feb 2026
Companies that share a holder
- Invesco Ltd. also filed stake reports on 93 other companies: Alignment Healthcare Inc (Nov 2026), ArcBest Corp (Nov 2026), Canaan Inc (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 378 other companies: 4D MOLECULAR THERAPEUTICS INC (Nov 2026), ACADIA PHARMACEUTICALS INC (Nov 2026), ALBEMARLE CORP (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/adma-biologics